Ventolin (albuterol) / GSK - LARVOL DELTA

Drug-associated psoriasis: a pharmacovigilance study based on the FAERS database. (PubMed, Front Pharmacol) - "These signals involved several pharmacological categories, including anti-infective agents (e.g., Abacavir, Fluconazole, Moxifloxacin, Sulfamethoxazole), anti-inflammatory and immunomodulatory drugs (e.g., Celecoxib, Tofacitinib), cardiovascular agents (e.g., Acebutolol, Telmisartan, Clonidine), neuropsychiatric drugs (e.g., Nortriptyline, Temazepam, Zopiclone, Wellbutrin), hormonal agents (e.g., Progesterone, Prometrium), and respiratory medications (e.g., Ventolin). Our findings suggest that multiple drug classes are associated with psoriasis signals in pharmacovigilance data. These results highlight the importance of early recognition of drug-associated psoriasis and may assist clinicians in medication review and risk stratification in routine practice."

Adverse events • Journal • Cardiovascular • Dermatology • Immunology • Psoriasis • Psychiatry

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: University of Tennessee Graduate School of Medicine | Recruiting ➔ Completed

Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD) (clinicaltrials.gov) - P4 | N=280 | Not yet recruiting | Sponsor: University of Tennessee Graduate School of Medicine

New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Real-time metered dose inhalers (MDIs) characterization by secondary electrospray ionization (SESI)-mass spectrometry: a proof-of-principle study. (PubMed, Anal Methods) - "The analysis includes one of the most widely used inhalers worldwide, Ventolin®, a simple formulation containing salbutamol and norflurane for which salbutamol was reliably detected, while norflurane remained undetectable due to its low proton affinity; and Ventoduo®, a multicomponent formulation also including beclomethasone dipropionate, ethanol, and oleic acid for which all major components were successfully detected. The coupling of SESI with high-resolution MS enabled unambiguous identification of all analytes, with excellent mass accuracy, confirming the identity of both active ingredients through characteristic fragmentation patterns. These results demonstrate that SESI-MS, particularly when coupled with high-resolution instrumentation (SESI-HRMS), is a powerful and reliable tool for the comprehensive and real-time analysis of pharmaceutical aerosols, including those with multiple active ingredients and co-solvents."

Journal

In vitro comparison of aerosol deposition by albuterol pMDI using corrugated tubing versus a commercial spacer. (PubMed, Int J Pharm) - "This study quantitatively compared in vitro aerosol deposition of albuterol (Ventolin®) delivered under three setups: with a 6'' corrugated tubing spacer, with a commercially available spacer device (E-Chamber La Grande) and without a spacer...Commercial spacers remain the preferred option in practice, although performance depends on device configuration and test conditions. Further optimisation of affordable spacer designs is warranted for resource limited environments."

Journal • Preclinical • Anesthesia

CQVM149C2301: A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma. (clinicaltrialsregister.eu) - P2/3 | N=37 | Not yet recruiting | Sponsor: Novartis Pharma AG

New P2/3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Ventilation and Perfusion in Asthmatics (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: University of Miami | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The Role Intraoperative Salbutamol Inhaler in Preventing Atelectasis (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: King Abdullah University Hospital

New P1 trial • Respiratory Diseases

CHHEF: Effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure (clinicaltrialsregister.eu) - P4 | N=60 | Recruiting | Sponsor: Hospital General Universitario Gregorio Maranon | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

224295: eValuating the efficacy and safety of InitiatinG depemokImab earLy therApy iN COPD with Type 2 inflammation (VIGILANT) (clinicaltrialsregister.eu) - P2/3 | N=165 | Not yet recruiting | Sponsor: Glaxosmithkline Research & Development Limited

New P2/3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

222725: Depemokimab as an Extended treatmeNt DURation biologic in Adults with COPD and type 2 inflammation (ENDURA-1). (clinicaltrialsregister.eu) - P2/3 | N=327 | Recruiting | Sponsor: Glaxosmithkline Research & Development Limited

New P2/3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

222714: Depemokimab as an Extended treatmeNt DURation biologic in Adults with COPD and type 2 inflammation (ENDURA-1). (clinicaltrialsregister.eu) - P2/3 | N=453 | Recruiting | Sponsor: Glaxosmithkline Research & Development Limited

New P2/3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery (clinicaltrials.gov) - P=N/A | N=66 | Not yet recruiting | Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

New trial • Obesity

In Vitro Inhalation and Deposition of Salbutamol in Upper Airway Geometries. (PubMed, Pharm Res) - "Subject-specific airway models are not inherently more realistic than simplified models. When physiological features of oral inhalation-specifically soft palate elevation and a smaller mouth opening than a fully opened mouth-are not captured in the model geometry, simplified geometries based on oral inhalation conditions may more accurately represent true deposition patterns than subject-specific models derived from restful breathing CT scans."

Journal • Preclinical

CAN A NEW PORTABLE-VALVED HOLDING CHAMBER (VHC) FOR USE ON THE GO DELIVER RELIEVER MEDICATION EFFECTIVELY AND IMPROVE VHC USE ADHERENCE? (CHEST 2025) - "This laboratory study compared the particle size distribution and therefore potential lung delivery of an albuterol MDI (Ventolin*) when administered alone versus the new portable VHC (AeroChamber2go*, A2GO) and a widely prescribed standard VHC (AeroChamber Plus* Flow-Vu*, ACFV)... This study showed that the new portable VHC produced similar FPM to the widely used standard size VHC, both being a little higher than the MDI alone if coordination was perfect. CLINICAL IMPLICATIONS: Such perfect actuation-inhalation coordination is known to be a challenge, hence the requirement in many cases to optimize consistent medication delivery through use of a VHC. Given the effective drug delivery demonstrated with the more portable AeroChamber2go* VHC in this study, it would appear to be a good choice to improve adherence to use of a VHC on the go for delivery of reliever medication."

Adherence

Formulary optimisation to reduce greenhouse gas emissions from inhalers: a retrospective audit of dispensing data (ERS 2025) - "Changing the preferred salbutamol MDI inhaler from Ventolin™ to Salamol™ significantly reduced GHG emissions. This demonstrates that formulary optimisation is an effective way to reduce the environmental impact of inhalers."

Retrospective data

Impact of Financial Incentives on Greener Inhaler Prescribing: A Retrospective Observational Study Using National Primary Care Data in England (ERS 2025) - "The financial incentives did not significantly reduce MDI use in England, where MDI use remains among the highest in Europe. The scheme was more effective when prescribing changes did not necessitate a device switch or in-person patient education, such as Ventolin to Salamol, which could be facilitated via remote communication (phone call, bulk text messages, or emails). These findings underscore the limitations of financial incentives alone in driving environmentally sustainable inhaler prescribing."

Observational data • Retrospective data • Genetic Disorders • Obesity

Hospital inhaler waste – what are we throwing away? (ERS 2025) - "For relievers without dose counters (Salamol and Ventolin) 47.5% (152/302) had >90% of doses remaining... A high proportion of inhalers returned to hospital pharmacies are either unused or almost full. The presence of a dose counter does not significantly impact upon this in hospital settings. 1."

Clinical • Respiratory Diseases

Balancing efficacy and portability: comparative in vitro/in vivo evaluation of MDI PLUS® versus AeroChamber2go™ spacers for aerosol delivery. (PubMed, J Asthma) - "In vitro, aerosol characteristics were assessed using an Andersen cascade impactor at 28.3 L/min with Ventolin® pMDI (5 puffs, 100 µg/puff); HPLC quantified drug deposition on each stage...Both the MDI PLUS® and the AeroChamber2go™ significantly enhanced pulmonary delivery and reduced systemic exposure compared to pMDI alone, while MDI PLUS® might potentially show a superior ease of use. These findings support the adoption of either device to optimize inhaler therapy."

Journal • Preclinical • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

COMPIS: Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment (clinicaltrials.gov) - P=N/A | N=18 | Completed | Sponsor: Vastra Gotaland Region | Enrolling by invitation ➔ Completed | Trial completion date: Dec 2025 ➔ Mar 2025 | Trial primary completion date: Dec 2025 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Musculoskeletal Diseases • Myositis

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=118 | Completed | Sponsor: AstraZeneca | Trial completion date: Oct 2025 ➔ Jun 2025 | Trial primary completion date: Oct 2025 ➔ Jun 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Assessment of a Valved Holding Chamber for Delivering Inhaled Medication Through a Tracheostomy Tube in a Tidal Breathing Model (ATS 2025) - " Albuterol (Ventolin™, 2-actuations) was delivered to the model via 2 different valved holding chambers (VHC, AEROTRACH PLUS® Anti-Static VHC and PARI® VORTEX® Tracheo Non-Electrostatic Holding Chamber) via 4.5mm or 8.0mm TTs... The choice of a metered-dose inhaler / VHC delivery system can significantly influence treatment efficacy. This study demonstrated that the AEROTRACH PLUS® Anti-Static VHC provided superior delivery of albuterol compared to the PARI® VORTEX® Tracheo Non-Electrostatic Holding Chamber (p<0.001). Optimizing lung deposition with the AEROTRACH PLUS® spacer may lead to faster symptom relief and potentially reduce the required number of actuations and cost of treatment."

Pediatrics • Pulmonary Disease • Respiratory Diseases

Patients with asthma reminded of the increased risk of severe asthma attacks from overusing blue inhalers (GOV.UK) - "The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding patients with asthma of the importance of using their preventer (anti-inflammatory) inhaler regularly as prescribed, and to avoid relying on their blue inhaler alone. This is because without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks. This reminder follows updates to product information and the National Institute for Health and Care Excellence (NICE) guidance for short-acting beta 2 agonists (SABAs), including salbutamol and terbutaline, which are used to relieve sudden asthma symptoms such as chest tightness, wheezing, coughing and breathlessness."

NICE • Asthma

Role of Salbutamol in the Management of Transient Tachypnea of the New Born (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Khyber Teaching Hospital

New P1 trial

A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Children's Hospital and Institute of Child Health, Multan

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases